{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T16:21:47Z","timestamp":1754151707506,"version":"3.41.2"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,20]]},"DOI":"10.7759\/cureus.88362","type":"journal-article","created":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T13:14:56Z","timestamp":1753017296000},"source":"Crossref","is-referenced-by-count":0,"title":["From Felbamate to Carbamazepine: Clinical Consequences of Unintentional Antiepileptic Substitution in Refractory Epilepsy"],"prefix":"10.7759","author":[{"given":"Natanael","family":"Duarte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omarlyn","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elidenia","family":"Vel\u00e1squez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.120.019539","article-title":"Drug resistance in epilepsy: clinical impact, potential mechanisms, and new innovative treatment options","volume":"72","author":"L\u00f6scher W","year":"2020","unstructured":"L\u00f6scher W, Potschka H, Sisodiya SM, Vezzani A. Drug resistance in epilepsy: clinical impact, potential mechanisms, and new innovative treatment options. Pharmacol Rev. 2020, 72:606-38. 10.1124\/pr.120.019539","journal-title":"Pharmacol Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2023.03.006","article-title":"Risk factors for drug-resistant epilepsy in adult patients","volume":"160","author":"Lagger I","year":"2023","unstructured":"Lagger I, Garino E, Martinez O, Knorre E, Ernst G, Burgue\u00f1o AL. Risk factors for drug-resistant epilepsy in adult patients. Med Clin (Barc). 2023, 160:547-50. 10.1016\/j.medcli.2023.03.006","journal-title":"Med Clin (Barc)"},{"key":"ref3","article-title":"Lennox-Gastaut Syndrome","author":"Amrutkar CV","year":"2025","unstructured":"Amrutkar CV, Lui F. Lennox-Gastaut Syndrome. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2025."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-017-3188-y","article-title":"Lennox-Gastaut syndrome: a comprehensive review","volume":"39","author":"Asadi-Pooya AA","year":"2018","unstructured":"Asadi-Pooya AA. Lennox-Gastaut syndrome: a comprehensive review. Neurol Sci. 2018, 39:403-14. 10.1007\/s10072-017-3188-y","journal-title":"Neurol Sci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci13091305","article-title":"A comprehensive review of emerging trends and innovative therapies in epilepsy management","volume":"13","author":"Ghosh S","year":"2023","unstructured":"Ghosh S, Sinha JK, Ghosh S, Sharma H, Bhaskar R, Narayanan KB. A comprehensive review of emerging trends and innovative therapies in epilepsy management. Brain Sci. 2023, 13:1305. 10.3390\/brainsci13091305","journal-title":"Brain Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000000282","article-title":"Potential clinical and economic impact of switching branded medications to generics","volume":"24","author":"Straka RJ","year":"2017","unstructured":"Straka RJ, Keohane DJ, Liu LZ. Potential clinical and economic impact of switching branded medications to generics. Am J Ther. 2017, 24:e278-89. 10.1097\/MJT.0000000000000282","journal-title":"Am J Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00784-8","article-title":"Expanding the treatment landscape for Lennox-Gastaut syndrome: current and future strategies","volume":"35","author":"Strzelczyk A","year":"2021","unstructured":"Strzelczyk A, Schubert-Bast S. Expanding the treatment landscape for Lennox-Gastaut syndrome: current and future strategies . CNS Drugs. 2021, 35:61-83. 10.1007\/s40263-020-00784-8","journal-title":"CNS Drugs"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003277.pub3","article-title":"Treatment of Lennox-Gastaut syndrome","volume":"2013","author":"Hancock EC","year":"2013","unstructured":"Hancock EC, Cross JH. Treatment of Lennox-Gastaut syndrome. Cochrane Database Syst Rev. 2013, 2013:CD003277. 10.1002\/14651858.CD003277.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/epi4.13075","article-title":"Refining management strategies for Lennox-Gastaut syndrome: updated algorithms and practical approaches","volume":"10","author":"Auvin S","year":"2025","unstructured":"Auvin S, Arzimanoglou A, Falip M, Striano P, Cross JH. Refining management strategies for Lennox-Gastaut syndrome: updated algorithms and practical approaches. Epilepsia Open. 2025, 10:85-106. 10.1002\/epi4.13075","journal-title":"Epilepsia Open"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.01041.x","article-title":"Idiosyncratic adverse reactions to antiepileptic drugs","volume":"48","author":"Zaccara G","year":"2007","unstructured":"Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia. 2007, 48:1223-44. 10.1111\/j.1528-1167.2007.01041.x","journal-title":"Epilepsia"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-024-00462-x","article-title":"Investigating the relationship between anti-seizure medications and bleeding disorders: a comprehensive review of the current literature","volume":"12","author":"Mansoor A","year":"2025","unstructured":"Mansoor A, Shahzad M, Zulfiqar E, et al.. Investigating the relationship between anti-seizure medications and bleeding disorders: a comprehensive review of the current literature. Drugs Real World Outcomes. 2025, 12:1-15. 10.1007\/s40801-024-00462-x","journal-title":"Drugs Real World Outcomes"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12732","article-title":"The efficacy and tolerability of pharmacologic treatment options for Lennox-Gastaut syndrome","volume":"55 Suppl 4","author":"Montouris GD","year":"2014","unstructured":"Montouris GD, Wheless JW, Glauser TA. The efficacy and tolerability of pharmacologic treatment options for Lennox-Gastaut syndrome. Epilepsia. 2014, 55 Suppl 4:10-20. 10.1111\/epi.12732","journal-title":"Epilepsia"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199301073280105","article-title":"Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome)","volume":"328","year":"1993","unstructured":"Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). N Engl J Med. 1993, 328.29-33. 10.1056\/NEJM199301073280105","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1993.tb04590.x","article-title":"Felbamate in the treatment of Lennox-Gastaut syndrome: results of a 12-month open-label study following a randomized clinical trial","volume":"34 Suppl 7","author":"Dodson WE","year":"1993","unstructured":"Dodson WE. Felbamate in the treatment of Lennox-Gastaut syndrome: results of a 12-month open-label study following a randomized clinical trial. Epilepsia. 1993, 34 Suppl 7:S18-24. 10.1111\/j.1528-1157.1993.tb04590.x","journal-title":"Epilepsia"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1177\/106002809002401214","article-title":"A review of carbamazepine's hematologic reactions and monitoring recommendations","volume":"24","author":"Sobotka JL","year":"1990","unstructured":"Sobotka JL, Alexander B, Cook BL. A review of carbamazepine's hematologic reactions and monitoring recommendations. DICP. 1990, 24:1214-9. 10.1177\/106002809002401214","journal-title":"DICP"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.44.s.2.1.x","article-title":"Chronic management of seizures in the syndromes of idiopathic generalized epilepsy","volume":"44 Suppl 2","author":"Bourgeois BF","year":"2003","unstructured":"Bourgeois BF. Chronic management of seizures in the syndromes of idiopathic generalized epilepsy. Epilepsia. 2003, 44 Suppl 2:27-32. 10.1046\/j.1528-1157.44.s.2.1.x","journal-title":"Epilepsia"},{"key":"ref17","article-title":"Carbamazepine","author":"Maan JS","year":"2025","unstructured":"Maan JS, Duong T vi H, Saadabadi A. Carbamazepine. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2025."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/361995-from-felbamate-to-carbamazepine-clinical-consequences-of-unintentional-antiepileptic-substitution-in-refractory-epilepsy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T13:14:56Z","timestamp":1753017296000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/361995-from-felbamate-to-carbamazepine-clinical-consequences-of-unintentional-antiepileptic-substitution-in-refractory-epilepsy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,20]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.88362","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,7,20]]}}}